AU2018236336B2 - Analogs of deutetrabenazine, their preparation and use - Google Patents

Analogs of deutetrabenazine, their preparation and use Download PDF

Info

Publication number
AU2018236336B2
AU2018236336B2 AU2018236336A AU2018236336A AU2018236336B2 AU 2018236336 B2 AU2018236336 B2 AU 2018236336B2 AU 2018236336 A AU2018236336 A AU 2018236336A AU 2018236336 A AU2018236336 A AU 2018236336A AU 2018236336 B2 AU2018236336 B2 AU 2018236336B2
Authority
AU
Australia
Prior art keywords
deutetrabenazine
compound
concentration
pharmaceutical composition
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018236336A
Other languages
English (en)
Other versions
AU2018236336A1 (en
Inventor
Jim Kerr
Chengzi ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auspex Pharmaceuticals Inc
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AU2018236336A1 publication Critical patent/AU2018236336A1/en
Application granted granted Critical
Publication of AU2018236336B2 publication Critical patent/AU2018236336B2/en
Priority to AU2022203369A priority Critical patent/AU2022203369B2/en
Assigned to AUSPEX PHARMACEUTICALS LLC reassignment AUSPEX PHARMACEUTICALS LLC Amend patent request/document other than specification (104) Assignors: AUSPEX PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
AU2018236336A 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use Active AU2018236336B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203369A AU2022203369B2 (en) 2017-03-15 2022-05-18 Analogs of deutetrabenazine, their preparation and use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
US62/471,484 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203369A Division AU2022203369B2 (en) 2017-03-15 2022-05-18 Analogs of deutetrabenazine, their preparation and use

Publications (2)

Publication Number Publication Date
AU2018236336A1 AU2018236336A1 (en) 2019-10-24
AU2018236336B2 true AU2018236336B2 (en) 2022-02-24

Family

ID=61873991

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018236336A Active AU2018236336B2 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use
AU2022203369A Active AU2022203369B2 (en) 2017-03-15 2022-05-18 Analogs of deutetrabenazine, their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203369A Active AU2022203369B2 (en) 2017-03-15 2022-05-18 Analogs of deutetrabenazine, their preparation and use

Country Status (20)

Country Link
US (4) US11813232B2 (enExample)
EP (1) EP3596077A1 (enExample)
JP (3) JP7608050B2 (enExample)
KR (2) KR20200003791A (enExample)
CN (1) CN110709398A (enExample)
AR (1) AR111182A1 (enExample)
AU (2) AU2018236336B2 (enExample)
BR (1) BR112019018966A2 (enExample)
CA (1) CA3056612A1 (enExample)
CL (1) CL2019002629A1 (enExample)
CO (1) CO2019011271A2 (enExample)
EA (1) EA201992168A1 (enExample)
IL (1) IL269132A (enExample)
MX (1) MX2019010913A (enExample)
PE (1) PE20191819A1 (enExample)
SG (1) SG11201908477QA (enExample)
TW (1) TWI772382B (enExample)
UA (1) UA127052C2 (enExample)
WO (1) WO2018170214A1 (enExample)
ZA (1) ZA201906326B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113395966A (zh) * 2018-12-13 2021-09-14 奥斯佩克斯医药公司 用于治疗脑瘫中的运动障碍的方法
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
PE20230852A1 (es) * 2020-06-10 2023-05-29 Auspex Pharmaceuticals Inc Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
US20160222008A1 (en) * 2012-09-18 2016-08-04 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
CA2930744A1 (en) * 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
US20160222008A1 (en) * 2012-09-18 2016-08-04 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Also Published As

Publication number Publication date
JP7608050B2 (ja) 2025-01-06
AU2022203369B2 (en) 2024-04-04
JP7631572B2 (ja) 2025-02-18
TW201840317A (zh) 2018-11-16
JP2024050724A (ja) 2024-04-10
US20200016148A1 (en) 2020-01-16
WO2018170214A1 (en) 2018-09-20
US11179386B2 (en) 2021-11-23
US20220088006A1 (en) 2022-03-24
US11813232B2 (en) 2023-11-14
CL2019002629A1 (es) 2020-01-24
IL269132A (en) 2019-11-28
PE20191819A1 (es) 2019-12-27
MX2019010913A (es) 2020-01-20
ZA201906326B (en) 2022-12-21
CO2019011271A2 (es) 2020-02-28
AU2022203369A1 (en) 2022-06-09
US20220040170A1 (en) 2022-02-10
EA201992168A1 (ru) 2020-03-16
EP3596077A1 (en) 2020-01-22
SG11201908477QA (en) 2019-10-30
NZ757789A (en) 2024-08-30
KR20230003308A (ko) 2023-01-05
JP2023010754A (ja) 2023-01-20
UA127052C2 (uk) 2023-03-29
US20180263972A1 (en) 2018-09-20
BR112019018966A2 (pt) 2020-04-22
KR20200003791A (ko) 2020-01-10
JP2020510073A (ja) 2020-04-02
CN110709398A (zh) 2020-01-17
CA3056612A1 (en) 2018-09-20
AR111182A1 (es) 2019-06-12
TWI772382B (zh) 2022-08-01
AU2018236336A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
AU2022203369B2 (en) Analogs of deutetrabenazine, their preparation and use
JP2020143072A (ja) プリドピジンの類似体、それらの製造および使用
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
EP2094675B1 (en) A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
JP5986635B2 (ja) ５，６，７，８−テトラヒドロ−６−［ｎ，ｎ−ビス［（２−チエニル）エチル］］アミノ−１−ナフトール、及びその作製方法、及びその使用
JP2877231B2 (ja) スピロキヌクリジン誘導体の光学異性体、それらの製造法、それらからなる薬剤組成物およびそれらを使用した治療法
EP3985009B1 (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
CN110272349B (zh) 一种2’-羟基-3苯基苯丙酮化合物及其制备方法和用途
HK40018479A (en) Analogs of deutetrabenazine, their preparation and use
CN114644642A (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
EA044519B1 (ru) Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством
TW202542164A (zh) 治療過動性運動障礙之化合物
CN105585576A (zh) 银杏内酯k晶l型及制备方法和其组合物与用途
CN118359619A (zh) 一种抗抑郁化合物的盐、其制备方法、包含其的药物组合物及其用途
HK40072843A (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
EP0460358A2 (en) Agent for treating disorders from cerebral neuro-degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AUSPEX PHARMACEUTICALS LLC

Free format text: FORMER NAME(S): AUSPEX PHARMACEUTICALS, INC.